Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GEMOX-B in Advanced Biliary Tract and Gallbladder Cancer
NCT00361231Phase 2Completed
- Sponsor
- Massachusetts General Hospital
- Start
- May 2006
- Primary completion
- Mar 2009
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of bevacizumab in biliary tract cancer (BTC) and gallbladder adenocarcinoma, sponsored by Massachusetts General Hospital. Primary endpoint: Median Progression Free Survival at 2 years. Started May 2006; status: completed.
02
Drugs
bevacizumab
03
Conditions
biliary tract cancer (BTC)gallbladder adenocarcinoma
Beyond the preview
Go deeper on NCT00361231.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00361231.